Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 14 new employees hired in November 2024. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 8,040 restricted stock units (RSUs). These RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary. The equity awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Sarepta Therapeutics (NASDAQ:SRPT) ha concesso premi azionari a 14 nuovi dipendenti assunti nel novembre 2024. I premi, approvati nell'ambito del Piano di Incentivo per l'Inizio dell'Occupazione 2024 dell'azienda, consistono in 8.040 unit脿 di azioni vincolate (RSU). Queste RSU matureranno nell'arco di quattro anni, con un quarto che matura annualmente all'anniversario della data di concessione. I premi azionari sono stati concessi come incentivi all'occupazione in conformit脿 con la Regola 5635(c)(4) del Nasdaq.
Sarepta Therapeutics (NASDAQ:SRPT) ha otorgado premios en acciones a 14 nuevos empleados contratados en noviembre de 2024. Los premios, aprobados bajo el Plan de Incentivo para el Inicio de Empleo 2024 de la compa帽铆a, consisten en 8,040 unidades de acciones restringidas (RSUs). Estas RSUs se consolidar谩n durante cuatro a帽os, con un cuarto consolid谩ndose anualmente en el aniversario de la fecha de concesi贸n. Los premios en acciones se otorgaron como incentivos laborales en cumplimiento con la Regla 5635(c)(4) de Nasdaq.
靷爤頂勴儉 旃橂鞝� (NASDAQ:SRPT)電� 2024雲� 11鞗旍棎 毂勳毄霅� 14氇呾潣 鞁犼窚 歆侅洂鞐愱矊 欤检嫕 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 鞚� 氤挫儊鞚� 須岇偓鞚� 2024雲� 瓿犾毄 鞁滌瀾 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞀轨澑霅橃棃鞙茧┌, 齑� 8,040臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)搿� 甑劚霅╇媹雼�. 鞚� RSU電� 4雲勳棎 瓯胳硱 攵勴暊 歆�旮夒悩鞏�, 攵�鞐澕鞚� 旮半厫鞚茧雼� 1/4鞚� 歆�旮夒惄雼堧嫟. 欤检嫕 氤挫儊鞚� 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 瓿犾毄 鞙犾澑鞙茧 鞝滉车霅橃棃鞀惦媹雼�.
Sarepta Therapeutics (NASDAQ:SRPT) a accord茅 des r茅compenses en actions 脿 14 nouveaux employ茅s recrut茅s en novembre 2024. Ces r茅compenses, approuv茅es dans le cadre du Plan d'Incitation 脿 l'Emploi 2024 de la soci茅t茅, se composent de 8 040 unit茅s d'actions restreintes (RSU). Ces RSU seront acquises sur une p茅riode de quatre ans, avec un quart acqu茅rant des droits annuellement 脿 l'anniversaire de la date de l'attribution. Les r茅compenses en actions ont 茅t茅 accord茅es comme incitations 脿 l'emploi conform茅ment 脿 la R猫gle 5635(c)(4) de Nasdaq.
Sarepta Therapeutics (NASDAQ:SRPT) hat 14 neuen Mitarbeitern, die im November 2024 eingestellt wurden, Aktienverg眉tungen 驳别飞盲丑谤迟. Die Verg眉tungen, die im Rahmen des 2024er Anreizplans f眉r Besch盲ftigungsbeginn des Unternehmens genehmigt wurden, bestehen aus 8.040 eingeschr盲nkten Aktieneinheiten (RSUs). Diese RSUs werden 眉ber vier Jahre ausgegeben, wobei jeweils ein Viertel am Jahrestag des Vergabedatums f盲llig wird. Die Aktienverg眉tungen wurden als Anreiz f眉r die Besch盲ftigung gem盲脽 Nasdaq-Listing-Regel 5635(c)(4) 驳别飞盲丑谤迟.
- None.
- None.
The employees received in the aggregate 8,040 restricted stock units (鈥淩SUs鈥�). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee鈥檚 continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta鈥檚 common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit or follow us on , , and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
View source version on businesswire.com:
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many RSUs did Sarepta Therapeutics (SRPT) grant in November 2024?
What is the vesting schedule for Sarepta Therapeutics' (SRPT) November 2024 RSU grants?
Did Sarepta Therapeutics (SRPT) include stock options in their November 2024 inducement grants?
